Pear Therapeutics
149 articles about Pear Therapeutics
-
It was a busy week for clinical trial announcements. Here's a look.
-
Pear Therapeutics Announces Data from Two Studies Evaluating Prescription Digital Therapeutics (PDTs) for Chronic Insomnia Presented at World Sleep Congress 2022
3/15/2022
Pear Therapeutics, Inc. today announced data that further underscore the effectiveness of Somryst®, the only FDA-authorized PDT for the treatment of chronic insomnia.
-
Pear Therapeutics to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on March 28, 2022 at 4:30 p.m. Eastern Time
3/14/2022
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host a conference call and webcast at 4:30 p.m. ET on Monday, March 28, 2022, to discuss its financial and operating results for the fourth quarter and full year of 2021.
-
Pear Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference
3/2/2022
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the 42nd Annual Cowen Healthcare Conference being held virtually on Wednesday, March 9.
-
Pear Therapeutics Announces Availability of reSET® and reSET-O® in Spanish
2/15/2022
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the launch of Spanish-language availability for reSET® and reSET-O®, the only FDA-authorized PDTs for the treatment of substance use disorder (SUD) and opioid use disorder (OUD), respectively.
-
Pear Therapeutics Announces Operational Performance Metrics for Full Year 2021 and Reaffirms Financial and Operational Performance Metrics for Full Year 2022
1/18/2022
Pear Therapeutics Announces Operational Performance Metrics for Full Year 2021 and Reaffirms Financial and Operational Performance Metrics for Full Year 2022.
-
Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics Company
12/3/2021
Pear Therapeutics, Inc. announced today the completion of its business combination with Thimble Point Acquisition Corp.
-
Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder
11/22/2021
Pear Therapeutics, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its reSET-A™ PDT product candidate designed for the treatment of alcohol use disorder (AUD).
-
Pear Therapeutics Provides 2021 Business Update and Reaffirms Full Year 2021 Revenue Guidance
11/15/2021
Pear Therapeutics Provides 2021 Business Update and Reaffirms Full Year 2021 Revenue Guidance.
-
Thimble Point and Pear Therapeutics Announce Additional $50 Million in Committed Capital to Fund Business Plan
11/15/2021
Today, Thimble Point Acquisition Corp, Inc. and Pear Therapeutics, Inc. jointly announced an additional commitment from an affiliate of Thimble Point’s sponsor of up to $50 million.
-
Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List
11/9/2021
Pear Therapeutics Announces Inclusion of reSET ® and reSET-O ® on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List
-
Pear Therapeutics to Participate in the BTIG Digital Health Forum
11/8/2021
Pear Therapeutics, Inc., the leader in developing and commercializing prescription digital therapeutics to treat serious disease, announced management’s participation in the virtual BTIG Digital Health Forum being held on Monday, November 15.
-
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021,
-
Pear Therapeutics Announces Publication Showing Cost Savings and Decreased Hospital Encounters for Opioid Use Disorder Patients Treated with reSET-O® Compared to Control Patients During Nine-Month Period Following Prescription
11/3/2021
Pear Therapeutics, Inc., today announced results from an analysis of real-world data evaluating healthcare resource utilization (HCRU) for reSET-O®, the first and only FDA-authorized prescription digital therapeutic (PDT) for the treatment of opioid use disorder (OUD).
-
Pear Therapeutics and Thimble Point Acquisition Corp. Announce Effectiveness of S-4 Registration Statement and Set November 23, 2021 for Thimble Point Special Stockholder Meeting to Vote on Proposed Business Combination
10/27/2021
Pear Therapeutics and Thimble Point Acquisition Corp. Announce Effectiveness of S-4 Registration Statement and Set November 23, 2021 for Thimble Point Special Stockholder Meeting to Vote on Proposed Business Combination
-
Pear Therapeutics Announces First State Medicaid Program Decision to Cover Prescription Digital Therapeutics
10/13/2021
Pear Therapeutics, Inc. today announced MassHealth, Massachusetts’ Medicaid program, has notified Pear of its intent to cover Pear’s prescription digital therapeutics (PDTs) reSET® and reSET-O® to fight the growing substance and opioid addiction crisis.
-
Pear Therapeutics to Participate in HLTH 2021 Conference and Evercore ISI Digital Therapeutics Virtual Bus Tour
10/8/2021
Pear Therapeutics, Inc. today announced management’s participation in the HLTH 2021 Conference and the Evercore ISI Digital Therapeutics Virtual Bus Tour.
-
Pear Therapeutics Continues to Expand Intellectual Property Portfolio for Prescription Digital Therapeutics
10/5/2021
Pear has built a foundational estate of intellectual property, including more than 20 owned and licensed patents covering more than 600 claims for a variety of different aspects related to prescription digital therapeutics (PDTs).
-
Pear Therapeutics to Participate in the Sachs Associates 8th Annual HealthTech Investment Forum
9/28/2021
Pear Therapeutics to Participate in the Sachs Associates 8th Annual HealthTech Investment Forum
-
Pear Therapeutics Announces Additional Coverage Decisions and Formulary Adoption of its Prescription Digital Therapeutics
9/23/2021
Pear Therapeutics, Inc. today updated the number of entities providing coverage for its three commercial products, reSET®, reSET-O®, and Somryst®.